Articles From: Data from Merck’s Investigational Hepatitis C Treatment Portfolio to be Presented at the 64th American Association for the Study of Liver Diseases Annual Meeting to Data Presented at ATTD 2014 Suggest t:slim® Insulin Pump Faster to Train with Fewer Use Errors than Competition


Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of data from studies evaluating the company’s investigational oral chronic hepatitis C virus (HCV) treatments MK-5172 and MK-8742 at the 64 th American Association for the Study of Liver Diseases Annual Meeting (AASLD). The meeting is scheduled to take place in Washington, D.C., Nov.
Sign-up for Data from Merck’s Investigational Hepatitis C Treatment Portfolio to be Presented at the 64th American Association for the Study of Liver Diseases Annual Meeting investment picks
2014/3/30
Data From Two Separate Phase 3 Studies of Evolocumab (AMG 145), a PCSK9 Inhibitor, Presented in Late-Breaking Clinical Trials Session at ACC.14 - Data Add to the Three Pivotal Studies Presented Yesterday Positive Results From GAUSS-2 Simultaneously Published in the Journal of the American College of Cardiology Robust Data Presented at ACC.14 From Five Phase 3 Studies in More Than 4,000 Patients Form the Basis of Global Filing Plan THOUSAND OAKS, Calif.
Sign-up for Data From Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Statin Intolerant Patients And In Patients On Statins investment picks
2013/9/24
Two pooled analyses of data from clinical trials in adults with type 2 diabetes, including the elderly with normal renal function to severe renal impairment, found similar incidence of adverse events for linagliptin compared with placebo RIDGEFIELD, Conn.
Sign-up for Data From Post-Hoc Analyses Presented at EASD Examine Safety Profile of Linagliptin in Adults with Type 2 Diabetes investment picks
http://media.marketwire.com/attachments/201207/48975_Medivation_logo_r.jpg http://media.marketwire.com/attachments/201207/48976_Astellas_logo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1077793&ProfileId=051205&sourceType=1 SAN FRANCISCO, CA and NORTHBROOK, IL --
Sign-up for Data From PREVAIL Trial of Enzalutamide in Chemotherapy-Naive Metastatic Prostate Cancer to Be Presented in Late-Breaking Session at ASCO GU Symposium investment picks
2013/12/10
Research by QlikTech (NASDAQ: QLIK ), a leader in user-driven Business Intelligence (BI), has found that, while data governance has become more important following the global financial crisis, nearly two thirds (63%) of financial industry executives do not consider it to be a board-level issue.
Sign-up for Data Governance Lacks Board-Level Support investment picks
2014/1/20
DATA Group Adopts Advance Notice By-law Canada NewsWire BRAMPTON, ON , Jan.
Sign-up for DATA Group Adopts Advance Notice By-law investment picks
DATA Group Inc. announces quarterly 2013 dividend Canada NewsWire About DATA Group Inc. DATA Group Inc. is a managed business communications services company specializing in customized document management and marketing solutions.
Sign-up for DATA Group Inc. announces quarterly 2013 dividend investment picks
Data Group Inc. announces second quarter results for 2013 Canada NewsWire Highlights Q2 2013 Second quarter 2013 ("Q2") Revenues of $77.8 million , Q2 Gross Profit of $19.8 million and Q2 Net Loss of $3.7 million (includes a Q2 restructuring charge of $5.2 million ) Q2 Dividends declared of $1.8 million or $0.075 per share Q2 Adjusted EBITDA of $5.8 million (See Table 2 and "Non-GAAP Measures" below) YTD 2013 Year to Date 2013 ("YTD") Revenues of $160.7 million , YTD Gross Profit of $41.5 million and YTD Net Loss of $2.8 million (includes a YTD restructuring charge of $6.0 million ) YTD Dividends declared of $3.5 million or $0.15 per share YTD Adjusted EBITDA of $13.1 million (See Table 2 and "Non-GAAP Measures" below) BRAMPTON, ON , Aug.
Sign-up for Data Group Inc. announces second quarter results for 2013 investment picks
DATA Group Inc. announces third quarter results for 2013 and changes to dividend policy Canada NewsWire HIGHLIGHTS Q3 2013 Third quarter 2013 ("Q3") Revenues of $74.1 million , Q3 Gross Profit of $17.7 million and Q3 Net Loss of $20.2 million (includes a Q3 restructuring charge of $0.6 million and a non-cash impairment of goodwill charge of $19.0 million ) Q3 Adjusted EBITDA of $4.4 million (See Table 2 and "Non-GAAP Measures" below) YTD 2013 Year to Date 2013 ("YTD") Revenues of $234.8 million , YTD Gross Profit of $59.2 million and YTD Net Loss of $23.0 million (includes a YTD restructuring charge of $6.6 million and a non-cash impairment of goodwill charge of $19.0 million ) YTD Adjusted EBITDA of $17.5 million (See Table 2 and "Non-GAAP Measures" below) BRAMPTON, ON , Nov.
Sign-up for DATA Group Inc. announces third quarter results for 2013 and changes to dividend policy investment picks
2013/11/1
DATA Group Inc. Third Quarter 2013 Earnings Results Conference Call Canada NewsWire Date: Friday, November 8, 2013 Time: 11:00 a.m. ET BRAMPTON, ON , Nov.
Sign-up for DATA Group Inc. Third Quarter 2013 Earnings Results Conference Call investment picks
DATA Group Ltd.
Sign-up for DATA Group Ltd. announces fourth quarter and year end results for 2013 investment picks
2014/2/28
DATA Group Ltd.
Sign-up for DATA Group Ltd. Fourth Quarter 2013 Earnings Results Conference Call investment picks
http://media.marketwire.com/attachments/201004/586398_dataiologo.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1053893&ProfileId=051205&sourceType=1 REDMOND, WA --
Sign-up for Data I/O Announces New PSV7000 High Performance Automated Programming System investment picks
2013/7/30
http://media.marketwire.com/attachments/201004/586398_dataiologo.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1038452&ProfileId=051205&sourceType=1 REDMOND, WA --
Sign-up for Data I/O Announces Rajeev Gulati as Chief Technology Officer investment picks
2014/2/18
http://media.marketwire.com/attachments/201004/586398_dataiologo.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1090867&ProfileId=051205&sourceType=1 REDMOND, WA --
Sign-up for Data I/O Corporation to Announce Fourth Quarter and 2013 Financial Results on February 27, 2014 investment picks
2013/10/10
http://media.marketwire.com/attachments/201004/586398_dataiologo.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1058559&ProfileId=051205&sourceType=1 REDMOND, WA --
Sign-up for Data I/O Corporation to Announce Third Quarter 2013 Financial Results on October 24, 2013 investment picks
2014/2/27
http://media.marketwire.com/attachments/201004/586398_dataiologo.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1093921&ProfileId=051205&sourceType=1 REDMOND, WA --
Sign-up for Data I/O Reports Fourth Quarter and Year 2013 Results investment picks
http://media.marketwire.com/attachments/201004/586398_dataiologo.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1038463&ProfileId=051205&sourceType=1 REDMOND, WA --
Sign-up for Data I/O Reports Second Quarter 2013 Results investment picks
http://media.marketwire.com/attachments/201004/586398_dataiologo.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1062361&ProfileId=051205&sourceType=1 REDMOND, WA --
Sign-up for Data I/O Reports Third Quarter 2013 Results investment picks
http://media.marketwire.com/attachments/201004/586398_dataiologo.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1048075&ProfileId=051205&sourceType=1 REDMOND, WA --
Sign-up for Data I/O to Present at the 2013 Gateway Conference on September 10 investment picks
2014/3/12
http://media.marketwire.com/attachments/201004/586398_dataiologo.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1097541&ProfileId=051205&sourceType=1 REDMOND, WA --
Sign-up for Data I/O to Showcase New Award Winning PSV7000 High Performance Automated Programming System at APEX investment picks
2013/11/13
http://media.marketwire.com/attachments/201004/586398_dataiologo.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1067881&ProfileId=051205&sourceType=1 REDMOND, WA --
Sign-up for Data I/O's PSV7000 Automated Programming System Wins Global Technology Award investment picks
2014/3/25
http://media.marketwire.com/attachments/201004/586398_dataiologo.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1100687&ProfileId=051205&sourceType=1 REDMOND, WA --
Sign-up for Data I/O's PSV7000 Automated Programming Wins APEX Best of Show for Programming investment picks
http://media.marketwire.com/attachments/201009/639319_logo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1066698&ProfileId=051205&sourceType=1 TUSTIN, CA --
Sign-up for Data Presentation at Society for Immunotherapy of Cancer Annual Meeting Supports Potential of Peregrine Pharmaceuticals' Novel Immunotherapy Bavituximab in Combination With Anti-CTLA-4 Antibodies investment picks
2013/9/26
Improvements in several indicators of diabetes management, including perceptions about hyperglycaemia and weight, observed for investigational GLP-1 receptor agonist BARCELONA, Spain , Sept.
Sign-up for Data Presented at 49th EASD Annual Meeting Show Treatment with Lilly's Investigational Dulaglutide Resulted in Improved Patient-Reported Health Outcomes investment picks
2014/4/9
http://media.marketwire.com/attachments/201009/639319_logo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1105381&ProfileId=051205&sourceType=1 TUSTIN, CA --
Sign-up for Data Presented at AACR Support Potential of Peregrine's PS-Targeting Immunotherapy Bavituximab to Enhance Anti-Tumor and Immune-Stimulating Effects of Anti-CTLA-4 and Anti-PD-1 Treatments in Models of Melanoma and Colon Cancer investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Data from Merck’s Investigational Hepatitis C Treatment Portfolio to be Presented at the 64th American Association for the Study of Liver Diseases Annual Meeting to Data Presented at ATTD 2014 Suggest t:slim® Insulin Pump Faster to Train with Fewer Use Errors than Competition
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity